

Baird Growth Stock Conference

May 20, 2010

Shire plc

Michael Cola

President, Specialty Pharmaceuticals



Our purpose

We enable people with life-altering conditions to lead better lives

THE “SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995


Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of Shire’s Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure new products for commercialization and/or development; government regulation of Shire’s products; Shire’s ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on Shire’s products; Shire’s ability to register, maintain and enforce patents and other intellectual property rights relating to its products; Shire’s ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in Shire’s filings with the Securities and Exchange Commission.

Shire's business model has been the key to our success

Business Model

- Specialty biopharmaceutical company
- Treatment of symptomatic diseases
- Small sales forces
- Focus on lower risk projects with relatively fast development timelines and strong IP protection

Financial impact past 7 years (2003 – 2009)



	% Growth	CAGR
Revenues	190%	16%
EBITDA	169%	15%

Note: data covers timeframe of 1/1/2003 through 12/31/2009

Strategy is delivering

Focused on the needs of patients

VPRIV (velaglucerase alfa) and REPLAGAL currently addressing unmet needs

Launching new products

INTUNIV – first and only selective $\alpha 2A$ agonist indicated for the treatment of ADHD

Acquisitions and geographic expansion

Presence in 28 countries and growing


Pipeline opportunities for long term growth

Progress in development programs, antithrombotic, CarrierWave technology, HGT research, and new technology (Santaris)

Sustaining our financial performance


Aspiration to grow sales in the mid-teens range year-on-year on average over the course of 2009 through 2015

Q1 2010 Core products replenishing the XR gap




2010 Q1 Core product sales growth



Q1 2008
\$370m



Q1 2009
\$460m




Q1 2010
\$626m



Vyvanse continues to grow share and volume

Vyvanse TRx Volume and Share June 2007 – April 2010




To be as brave as the people we help

Source: IMS NPA Monthly

VYVANSE Adult share continues to grow

Adult Market Share




INTUNIV Launch update

- Although it is still early post launch for INTUNIV, we are very encouraged by the early indicators
 - For the week ending May 7th, 2010, the overall national market share was 1.8%, and it is significantly higher in the important child / adolescent psychiatry and general psychiatry subsets of prescribers
 - Approximately 15,000 physicians have prescribed INTUNIV
 - Payors: formulary status still being reviewed by managed care plans. Currently most commercial managed care plans providing unrestricted access. Medicaid reimbursement progressing as expected

Shire GI Portfolio – April TRx Share = 33.8%

Shire GI Portfolio Oral 5-ASA Monthly TRx Share



Select growth opportunities for Specialty Pharma portfolio

- INTUNIV: continuing progress on life cycle opportunities
 - On-going studies to evaluate efficacy in combination with stimulants and evening dosing
- VYVANSE non-ADHD: Phase 2 clinical trials actively enrolling patients with data beginning in 2011
 - Adjunctive therapy in depression
 - Cognitive impairment in depression
 - Negative symptoms and cognitive impairment in schizophrenia
- Globalization of the ADHD portfolio
 - VYVANSE
 - Launched in Canada
 - Market authorization filings under review in Mexico and Brazil
 - Continued enrollment of EU registration trials
- LIALDA: global Phase 3 trials in diverticular disease are ongoing

Diverticular Disease

- Common disease that primarily afflicts patients over 50
 - Diverticular disease was the fifth most common reason for GI ambulatory care visits (NIDDK Burden of Digestive Disease, 2004)
- Acute episodes of diverticulitis are treated with antibiotics
- In 2008, approximately 2.25 million patients with uncomplicated diverticular disease received treatment for an acute attack
 - Repeat attacks often lead to surgical resection of afflicted portion of the colon
 - Approximately $\frac{1}{4}$ of patients with uncomplicated diverticular disease underwent elective surgery
 - 75% received conservative therapy, primarily acute antibiotic treatment followed by dietary alteration to include high fiber
 - No medications currently indicated for patient management beyond response to an acute attack (antibiotics)

SPD476 for Diverticular Disease

- Chronic Inflammation Offers a Plausible Etiology for Diverticular Disease
 - Diverticular disease produces variable clinical manifestations ranging from subclinical inflammation to generalized peritonitis
- SPD476, mesalamine, is a colonically targeted anti-inflammatory
- Clinical Program
 - The target population is patients with diverticular disease and a history of at least one prior attack of diverticulitis
 - Two Phase III, Randomized, Double-Blind, Dose-Response, Stratified, Placebo Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 Weeks to decrease the Recurrence of Diverticulitis
 - Enrollment for both trials is complete
- Target indication is long-term therapy to reduce the risk of recurrence of diverticulitis


Efforts continue to progress early pipeline products

- SPD 535 (anagrelide analogue) - platelet lowering ability without PDEIII inhibition
 - Initial PoC program targets prevention of thrombotic complications associated with arteriovenous grafts in hemodialysis
 - Proof-of-principle for broader utility as an anti-coagulant
 - Estimated data availability – H2 2010
- CarrierWave
 - Primarily focused in pain and ADHD
 - Estimated data availability – H2 2010


HGT - Product highlights

- ELAPRASE
 - Revenue up 22% versus Q1 2009
- VPRIV
 - Over 500 patients treated with VPRIV globally
 - Approved and launched in the US
 - Increasing number of patients on the VPRIV t-IND have initiated the commercial access process
 - Seeing strong demand from Gaucher patients who are new to VPRIV
- FIRAZYR
 - Now launched in 13 countries, including the 5 largest European countries
- REPLAGAL
 - Revenue up 69% versus Q1 2009
 - Market leader in EU with estimated 60% market share

190 patients added to REPLAGAL therapy in Q1 2010 with the majority coming from patient switches




2010 Key events



H2-2010

- VYVANSE data from Ph2 non-ADHD trials
- Additional Carrierwave program data available
- SPD 535 (anagrelide analogue) PoC data
- VPRIV EU approval expected
- REPLAGAL US rolling BLA submission targeted
- Manufacturing initiated in new large scale facility in MA

Potential launches from 2010-2016*



2010	2011	2012	2013-2016
<ul style="list-style-type: none">• VYVANSE (Canada)• FOSRENOL CKD (EU)• VPRIV (US&EU)• FIRAZYR (ROW)• REPLAGAL (US)	<ul style="list-style-type: none">• VYVANSE (Latin America)• FIRAZYR (US)• VPRIV (ROW)	<ul style="list-style-type: none">• VYVANSE (EU)	<ul style="list-style-type: none">• HGT 1110 (MLD)• IDURSULFASE-IT• SANFILIPPO ERT• HGT 2610 (GLD)• JUVISTA• LIALDA DIVERTICULITIS• SPD 535

*Subject to regulatory approvals

Solid foundation for future growth

- Delivering excellent Q1 results
 - Core product sales* up 36%
 - Strong cash generation and operating margins
- Replenished our product portfolio
 - Driving growth from balanced portfolio of 8 global products
 - Developing, advancing and enhancing our strong pipeline
- Increasing our global reach
 - Direct business in 28 countries and growing
- Aspiration to grow sales in the mid-teens range on average between 2009 and 2015

Questions and Answers



Our purpose

We enable people with life-altering conditions to lead better lives